StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

Arvinas r&d expenses

Research and development expenses are spending on new products and technology.

Arvinas's R&D Expenses for the twelve months ending Jun 30, 2026 was $238.70M, down 27.6% year over year. For fiscal 2025 it was $285.20M, down 18.1% from the year before. The highest annual figure on record is $379.70M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$285.20M-18.1%
FY2024Dec 31, 2024$348.20M-8.3%
FY2023Dec 31, 2023$379.70M+20.5%
FY2022Dec 31, 2022$315.00M+74.6%
FY2021Dec 31, 2021$180.40M+66.4%
FY2020Dec 31, 2020$108.40M+61.3%
FY2019Dec 31, 2019$67.20M+48.7%
FY2018Dec 31, 2018$45.19M+57.0%
FY2017Dec 31, 2017$28.79M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$52.60M-23.3%
Q1 FY2026Mar 31, 2026$60.30M-33.6%
Q4 FY2025Dec 31, 2025$61.10M-26.7%
Q3 FY2025Sep 30, 2025$64.70M-25.5%
Q2 FY2025Jun 30, 2025$68.60M-26.8%
Q1 FY2025Mar 31, 2025$90.80M+7.7%
Q4 FY2024Dec 31, 2024$83.30M-12.5%
Q3 FY2024Sep 30, 2024$86.90M+1.2%
Q2 FY2024Jun 30, 2024$93.70M-9.4%
Q1 FY2024Mar 31, 2024$84.30M-11.5%
Q4 FY2023Dec 31, 2023$95.20M-3.2%
Q3 FY2023Sep 30, 2023$85.90M+10.8%
Q2 FY2023Jun 30, 2023$103.40M+37.3%
Q1 FY2023Mar 31, 2023$95.30M+48.9%
Q4 FY2022Dec 31, 2022$98.30M+58.8%
Q3 FY2022Sep 30, 2022$77.50M+90.9%
Q2 FY2022Jun 30, 2022$75.30M+75.1%
Q1 FY2022Mar 31, 2022$64.00M+83.4%
Q4 FY2021Dec 31, 2021$61.90M+86.2%
Q3 FY2021Sep 30, 2021$40.60M+35.3%
Q2 FY2021Jun 30, 2021$43.00M+83.6%
Q1 FY2021Mar 31, 2021$34.90M+60.6%
Q4 FY2020Dec 31, 2020$33.24M+62.8%
Q3 FY2020Sep 30, 2020$30.01M+80.9%
Q2 FY2020Jun 30, 2020$23.42M+46.3%
Q1 FY2020Mar 31, 2020$21.73M+53.1%
Q4 FY2019Dec 31, 2019$20.41M+40.2%
Q3 FY2019Sep 30, 2019$16.59M+26.1%
Q2 FY2019Jun 30, 2019$16.00M+54.8%
Q1 FY2019Mar 31, 2019$14.19M+98.6%
Q4 FY2018Dec 31, 2018$14.56M+117.7%
Q3 FY2018Sep 30, 2018$13.15M+82.1%
Q2 FY2018Jun 30, 2018$10.34M+32.1%
Q1 FY2018Mar 31, 2018$7.14M+1.2%
Q4 FY2017Dec 31, 2017$6.69M–
Q3 FY2017Sep 30, 2017$7.22M–
Q2 FY2017Jun 30, 2017$7.82M–
Q1 FY2017Mar 31, 2017$7.06M–

More Arvinas figures

See a number that looks wrong?